KR20240118832A - 폴리펩티드 조절제 - Google Patents
폴리펩티드 조절제 Download PDFInfo
- Publication number
- KR20240118832A KR20240118832A KR1020247022359A KR20247022359A KR20240118832A KR 20240118832 A KR20240118832 A KR 20240118832A KR 1020247022359 A KR1020247022359 A KR 1020247022359A KR 20247022359 A KR20247022359 A KR 20247022359A KR 20240118832 A KR20240118832 A KR 20240118832A
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- syndrome
- polypeptide
- cancer
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288330P | 2021-12-10 | 2021-12-10 | |
| US63/288,330 | 2021-12-10 | ||
| PCT/US2022/081186 WO2023108073A2 (en) | 2021-12-10 | 2022-12-08 | Polypeptide modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240118832A true KR20240118832A (ko) | 2024-08-05 |
Family
ID=86731448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247022359A Pending KR20240118832A (ko) | 2021-12-10 | 2022-12-08 | 폴리펩티드 조절제 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051419A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444339A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546654A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240118832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613277A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022405109A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241913A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313360A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023108073A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026519808A (ja) * | 2023-06-06 | 2026-06-18 | ジョージアミューン・インコーポレイテッド | 新規pd-l2変異体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN106794235A (zh) * | 2014-07-18 | 2017-05-31 | 阿德瓦希斯公司 | 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| US11219694B2 (en) * | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| CN118085109A (zh) * | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| JP2020511144A (ja) * | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| WO2019060888A1 (en) * | 2017-09-25 | 2019-03-28 | New York University | HETÉRODIMÈRE-FC FUSION PROTEINS |
| US20210213063A1 (en) * | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3908600A1 (en) * | 2019-01-11 | 2021-11-17 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Fusion protein with immunosuppressive activity |
-
2022
- 2022-12-08 MX MX2024006897A patent/MX2024006897A/es unknown
- 2022-12-08 WO PCT/US2022/081186 patent/WO2023108073A2/en not_active Ceased
- 2022-12-08 CA CA3241913A patent/CA3241913A1/en active Pending
- 2022-12-08 IL IL313360A patent/IL313360A/en unknown
- 2022-12-08 KR KR1020247022359A patent/KR20240118832A/ko active Pending
- 2022-12-08 JP JP2024533810A patent/JP2024546654A/ja active Pending
- 2022-12-08 US US18/718,397 patent/US20250051419A1/en active Pending
- 2022-12-08 EP EP22905373.1A patent/EP4444339A4/en active Pending
- 2022-12-08 AU AU2022405109A patent/AU2022405109A1/en active Pending
- 2022-12-08 CN CN202280090526.6A patent/CN118613277A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024546654A (ja) | 2024-12-26 |
| WO2023108073A3 (en) | 2023-10-19 |
| CN118613277A (zh) | 2024-09-06 |
| EP4444339A2 (en) | 2024-10-16 |
| CA3241913A1 (en) | 2023-06-15 |
| MX2024006897A (es) | 2024-06-20 |
| AU2022405109A1 (en) | 2024-06-27 |
| US20250051419A1 (en) | 2025-02-13 |
| WO2023108073A2 (en) | 2023-06-15 |
| IL313360A (en) | 2024-08-01 |
| EP4444339A4 (en) | 2026-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7630426B2 (ja) | ヘテロ二量体fc融合タンパク質 | |
| JP7461350B2 (ja) | Arg1及び/又はarg2の阻害剤 | |
| ES2759075T3 (es) | Un anticuerpo monoclonal y un método del mismo | |
| KR20230146528A (ko) | 암을 치료하기 위한 방법 | |
| TWI812918B (zh) | IL-7Rαγc結合化合物 | |
| CA3169523A1 (en) | Transglutaminase-mediated conjugation | |
| JP7863349B2 (ja) | ガンマデルタt細胞を刺激するための方法及び組成物 | |
| EP3583113B1 (en) | Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma | |
| US20160304579A1 (en) | Polypeptides and uses thereof for treatment of autoimmune disorders and infection | |
| CN102203132A (zh) | Pd-1拮抗剂的组合物和使用方法 | |
| TW202132332A (zh) | IL—2Rβγc結合化合物 | |
| CA3127459A1 (en) | Compositions and methods for stimulating natural killer cells | |
| WO2016115218A1 (en) | Antibody drug conjugates for the treatment of immune conditions | |
| US20250051419A1 (en) | Polypeptide modulators | |
| KR20260021697A (ko) | 신규한 pd-l2 돌연변이체 | |
| HK40114371A (en) | Polypeptide modulators | |
| RU2792239C2 (ru) | Химерные белки на основе csf1r | |
| WO2025133213A1 (en) | Death receptor 5 (dr5)-armored car-t therapeutic | |
| TW202528536A (zh) | IL—2Rβγ促效劑肽在細胞製造中之用途 | |
| WO2023083439A1 (en) | Tlr7 agonist and combinations for cancer treatment | |
| HK40021169B (en) | Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma | |
| HK40021169A (en) | Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |